Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Trevena Inc | TRVN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.40 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.3227 - 1.35 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 0.40 | USD |
Trevena Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.33M | 18.32M | - | 3.13M | -40.29M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Trevena News
Date | Time | Source | News Article |
---|---|---|---|
5/17/2024 | 15:05 | Edgar (US Regulatory) | Form DEFR14A - Revised definitive proxy soliciting materials |
5/15/2024 | 06:15 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
5/15/2024 | 06:05 | Edgar (US Regulatory) | Form 8-K - Current report |
3/06/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
2/20/2024 | 15:06 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
2/14/2024 | 13:34 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
2/09/2024 | 15:05 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
2/01/2024 | 06:05 | Edgar (US Regulatory) | Form 8-K - Current report |
1/23/2024 | 15:15 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
1/22/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
1/19/2024 | 15:30 | Edgar (US Regulatory) | Form S-3/A - Registration statement under Securities Act of.. |
1/10/2024 | 15:30 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRVN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.395 | 0.4397 | 0.395 | 0.4079624 | 55,988 | 0.005 | 1.27% |
1 Month | 0.4198 | 0.4498 | 0.38 | 0.4147698 | 62,812 | -0.0198 | -4.72% |
3 Months | 0.57 | 0.59 | 0.3227 | 0.4166526 | 185,430 | -0.17 | -29.82% |
6 Months | 0.563 | 0.7693 | 0.3227 | 0.5048368 | 150,210 | -0.163 | -28.95% |
1 Year | 1.14 | 1.35 | 0.3227 | 0.8337495 | 392,849 | -0.74 | -64.91% |
3 Years | 44.00 | 55.00 | 0.3227 | 14.69 | 1,049,099 | -43.60 | -99.09% |
5 Years | 31.00 | 112.50 | 0.3227 | 40.14 | 1,919,823 | -30.60 | -98.71% |
Trevena Description
Trevena Inc is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain. |